Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer

Table 1 Correlation of uPA mRNA, uPAR mRNA and VEGF expression and clinicopathologic parameters in gastric cancer

Clinicopathologic parameters	n	uPA mRNA				uPAR mRNA				VEGF
		-	+	++	+++	-	+	++	+++	-	+	++	+++
Growth pattern
Expansive	48	29	8	3	8	21	8	8	11	24	6	8	10
Infiltrative	57	15	8	11	23b	14	7	17	19a	14	5	13	25a
Invasive depth
T1-T2	44	27	9	2	6	20	11	6	7	31	5	5	3
T3-T4	61	17	7	12	25b	15	4	19	23b	7	6	16	32b
Vessel invasion
Absent	29	16	8	2	3	14	8	2	5	25	3	1	0
Present	76	28	8	12	28b	21	7	23	25b	13	8	20	35b
Lymph node metastasis
Absent	35	21	8	3	3	17	8	2	8	27	5	1	2
Present	70	23	8	11	28	18	7	23	22	11	6	20	33b
Distant metastasis
Absent	63	39	16	1	7	29	14	8	12	36	10	10	7
Peritoneum metastasis	24	2	0	11	11b	2	0	11	11b	0	0	9	15b
Liver metastasis	18	3	0	2	13	4	1	6	7	2	1	2	13

^aP < 0.05, ^bP < 0.01.

Table 2 Correlation of MVD with uPA mRNA, uPAR mRNA and VEGF expression in gastric cancer

Expression	n	MVD (n/mm2)	t value	P value
uPA mRNA			11.25	0.005
+	61	64.89 ± 16.42
-	44	36.69 ± 14.94
uPAR mRNA			9.75	0.045
+	70	62.81 ± 19.93
-	35	39.39 ± 17.29
VEGF			12.25	0.005
+	67	65.72 ± 14.51
-	38	35.81 ± 13.36

Table 3 Correlation of uPA mRNA, uPAR mRNA, VEGF expression and MVD with survival time

Expression	n	Mean survival	5-yr survival	P value
		time (mo)	n (%)
uPA mRNA
-	44	115.9 ± 7.2	34 (78.9)	0.001
+	61	40.3 ± 6.7	11 (18.2)
uPAR mRNA
-	35	107.8 ± 8.8	26 (76.6)	0.002
+	70	49.6 ± 5.7	20 (29.0)
VEGF protein
-	38	123.3 ± 9.3	30 (81.0)	0.015
+	67	44.0 ± 7.6	16 (24.1)
MVD value
< 54.9	45	85.5 ± 6.8	35 (78.4)	0.006
≥ 54.9	60	38.7 ± 4.8	11 (18.6)